rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study (CONSERVE) | Aplastic Anemia & MDS International Foundation
rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study (CONSERVE)

Clinical Trial: NCT03829449

For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

Patients with diseases requiring complement inhibition who have previously taken part in Akari clinical trials and who wish to continue to receive rVA576 (Coversin) after their active participation in the previous trial has completed and patients treated under compassionate use or named patient arrangements who wish to continue on rVA576 (Coversin) therapy.

Status: 
Recruiting
Study Date: 
Mon, 03/13/2017 to Sun, 06/15/2025
Bone Marrow Disease(s): 
  • paroxysmal nocturnal hemoglobinuria (PNH)
Intervention: 
Experimental: rVA576 Coversin The study population will consist of patients who have completed participation in clinical trials under other Akari protocols and who wish to continue to receive rVA576 (Coversin) for up to 4 years. Drug: rVA576 (Coversin) The study population will consist of patients who have completed participation in clinical trials under other Akari protocols and who wish to continue to receive rVA576 (Coversin).